... MINEOLA N.Y. Feb. 5 /- Lenetix Inc. today announce... Risk assessment for Down syndrome is routinely offered to patients... We take deep pride in the technology we have developed because it... Pregnant women and their physicians are clamoring for an improved...

MINEOLA, N.Y., Feb. 5 /PRNewswire/ -- Lenetix, Inc. today announced the
launch of an Institutional Review Board (IRB)-approved screening study of an
improved first and second trimester non-invasive fetal diagnostic test to
detect Down syndrome. The Lenetix PloidYX(TM) maternal blood test promises to
be the most accurate and comprehensive test yet developed for the detection of
fetal aneuploidies, the presence of extra chromosomes, which cause Down
syndrome (T-21) and other chromosomal abnormalities.

Risk assessment for Down syndrome is routinely offered to patients in the
first and/or second trimester of pregnancy. These evaluations rely on indirect
ultrasound and biochemical exams, which are of imperfect accuracy. Patients
deemed "at risk" by these tests are generally referred for genetic counseling
and amniocentesis or CVS, invasive testing procedures which are known to cause
miscarriages. The Lenetix PloidYX technology directly interrogates the fetal
chromosomal status non-invasively, detecting not only Down syndrome (Trisomy
21), but other aneuploidies such as Trisomy 13, 18, and deviations in the
numbers of the sex chromosomes. The superior accuracy of the Lenetix test
promises fewer false positives and will therefore greatly reduce the number of
unnecessary invasive tests -- and the fetal losses they can cause.

"We take deep pride in the technology we have developed because it has the
potential to impact the lives of millions of women and their unborn children,"
said Lenetix president and CEO Leonard H. Kellner. "Patients and doctors are
constantly required to weigh the importance of an invasive and possibly
unneeded procedure against the possible harm it could cause, and we are
confident that this current IRB assessment is the next step towards making
that difficult decision unnecessary."

"Pregnant women and their physicians are clamoring for an improved, non-
invasive prenatal test for Down syndrome because they fear the risks of
amniocentesis," said Steve Brown, M.D., Lenetix Medical Director. "Our test
offers the promise of a comprehensive assessment of fetal aneuploidy in the
first trimester using a maternal blood sample. It's a higher-quality test that
will protect the mother and fetus."

"I'm personally honored to be involved in this clinical trial, because I
believe it will change Down syndrome testing forever," said Jonathan Herman,
M.D., a practicing obstetrician on Long Island. "No longer will I have to use
indirect tests, like proteins from the baby and mom, to figure out who is at
high risk. In the near future I will be able to test the chromosomes directly,
and that's very exciting."

About the Lenetix PloidYX Test

The Lenetix PloidYX Test makes use of methylation differences between the
fetal and maternal DNA that is found in maternal blood in order to achieve
selective amplification of the fetal component. Following amplification, a
microarray analysis makes it possible to determine the relative copy number of
all the chromosomes. An increase/decrease in the relative copy number of
chromosomes is indicative of trisomy or monosomy respectively.

About Lenetix, Inc.

Founded in 2001, Mineola, New York-based Lenetix(R), Inc is a privately
owned diagnostic laboratory providing innovative technologies focusing on
diagnostic testing and risk assessment in oncology, prenatal diagnosis and
assessment of genetic disease. The Lenetix scientific team has nearly 30 years
experience in developing new tests used by healthcare providers and
researchers worldwide. For more information, visit http://www.lenetix.com.

(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...

(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche. To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...

(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...

(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...

(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...